MIT spinoff Leuko introduces a groundbreaking non-invasive device to monitor white blood cell levels in chemotherapy patients. Using light and AI technology, this device aims to enhance patient comfort and revolutionize cancer treatment by enabling personalized chemotherapy dosages.